fool.com · 3 jul

Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?

Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how each company stacks up on growth, risk, and value.

zacks.com · 23 jun

Teva's Shift Beyond Generics Puts Focus on Branded Drug Growth

TEVA is expanding its branded drugs portfolio as Austedo, Ajovy and Uzedy drive higher-margin growth and reshape its business mix.

zacks.com · 19 jun

Teva Seeks FDA Nod for Ecopipam in Pediatric Tourette Syndrome

TEVA files an NDA with the FDA seeking approval of ecopipam for the treatment of pediatric Tourette syndrome.

fool.com · 19 jun

Teva Just Delivered More Good News on Its Biggest Growth Driver. Is the Stock Still a Bargain?

The company is seeing higher-margin growth, with EPS rising 72% year over year in the first quarter. The company's yearly guidance disappointed the markets.

globenewswire.com · 18 jun

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ecopipam, a first-in-class investigational therapy for the treatment of pediatric Tourette syndrome.

globenewswire.com · 18 jun

Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET

TEL AVIV, Israel and PARSIPPANY, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2026 financial results on Wednesday, July 29, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.

fool.com · 12 jun

Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock?

Teva has a handful of new biosimilars on the market, with more to come. Those assets will doubtlessly deliver some top-line growth.

businesswire.com · 11 jun

Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva Pharmaceutical

CHICAGO--(BUSINESS WIRE)--Paragon Biosciences today announced the closing of the sale of Emalex Biosciences to Teva Pharmaceutical, reinforcing Paragon's ability to build innovative biotechnology companies that deliver important treatments to the patients who need them. Emalex is another Paragon Biosciences-founded company built to develop a novel class of treatment for patients with central nervous system disorders, following in the footsteps of other successful Paragon companies such as Harmo.